Skip to search formSkip to main contentSkip to account menu

ledipasvir

Known as: Carbamic Acid, N-((1S)-1-(((6S)-6-(5-(9,9-difluoro-7-(2-((1R,3S,4S)-2-((2S)-2-((methoxycarbonyl)amino)-3-methyl-1-oxobutyl)-2-azabicyclo(2.2.1)hept-3-yl)-1H-benzimidazol-6-yl)-9H-fluoren-2-yl)-1H-imidazol-2-yl)-5-azaspiro(2.4)hept-5-yl)carbonyl)-2-methylpropyl)-, Methyl Ester, methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate 
An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against… 
National Institutes of Health

Related topics

Related topics

9 relations

Broader (3)

Antiviral AgentsBenzimidazolesFluorenes
Breast Cancer Resistance Protein Inhibitors [MoA]Hepatitis Cledipasvir / sofosbuvirledipasvir 90 MG / sofosbuvir 400 MG Oral Tablet [Harvoni]

Narrower (2)

GS-5885Harvoni

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes.
2017
2017
Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration
Data addressing real world effectiveness of direct acting antiviral agents in hepatitis C infected patients are now emerging… 
2017
2017
Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES
Directly acting antiviral agents (DAA) have been associated with hepatic decompensation, especially in patients with pre… 
Review
2017
Review
2017
Systematic review: interferon‐free regimens for patients with HCV‐related Child C cirrhosis
It is unclear whether the efficacy and long‐term outcome of treating patients with hepatitis C virus (HCV)‐positive cirrhosis… 
Review
2016
Review
2016
A clinician's guide to drug‐drug interactions with direct‐acting antiviral agents for the treatment of hepatitis C viral infection
The US Food and Drug Administration has recently approved a number of new direct‐acting antiviral agents for the treatment of… 
2016
2016
The cost‐effectiveness of testing for NS5a resistance‐associated polymorphisms at baseline in genotype 1a‐infected (treatment‐naïve and treatment‐experienced) subjects treated with all‐oral elbasvir…
The presence of baseline NS5A resistance‐associated variants (RAVs) impacted treatment response in HCV genotype 1a (GT1a… 
Highly Cited
2015
Highly Cited
2015
Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned.
Highly Cited
2015
Highly Cited
2015
O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3…
Review
2015
Review
2015
HCV targeting of patients with cirrhosis.
Review
2014
Review
2014
Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)